Strategic Focus Target researchers and executives in biotech and pharmaceutical companies pursuing ARI therapeutics, vaccines, or inhaled biologics, highlighting muco-trapping antibody platform as a differentiated route to treat RSV, influenza and other respiratory pathogens.

Clinical Progress Leverage the ongoing RSV human challenge trial and planned publications to position discussions around near-term clinical milestones, potential for accelerated timelines, and data-generating studies with pharma partners.

Regulatory & Partnering Position opportunities for collaboration with contract research organizations and larger biotech players seeking novel inhaled biologics platforms, emphasizing manufacturing scalability via engineered production cell lines and glycosylation control.

Funding Signals Capitalize on recent Series A financing and reported revenue activity to engage potential investors and strategic buyers, framing the company as an attractive early-stage platform with upside from expanded ARI indications.

Market Readiness Identify pharma distributors, contract manufacturers, and CROs as potential partners for rapid advancement, trial support, and scale-up in inhaled antibody delivery, leveraging the unique muco-trapping mechanism to differentiate in ARI pipelines.